Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC

Researchers hypothesized that pairing atezolizumab with bevacizumab would amplify the cancer-cell-killing effect of atezolizumab in patients with metastatic nonsquamous non-small-cell lung cancer (NSCLC).

Researchers hypothesized that pairing atezolizumab with bevacizumab would amplify the cancer-cell-killing effect of atezolizumab in patients with metastatic nonsquamous non-small-cell lung cancer (NSCLC). The theory underpinning the Phase III study was that bevacizumab, by blocking immunosuppression triggered by vascular endothelial growth factor, would allow atezolizumab to work harder and the immunotherapy to be more effective. Participants in the open-label IMpower150 trial, who had not previously undergone chemotherapy, were randomized to atezolizumab plus carboplatin plus paclitaxel, bevacizumab plus carboplatin plus paclitaxel (BCP), or atezolizumab plus BCP. The results indicated that the combination therapy of atezolizumab and bevacizumab, coupled with chemotherapy, significantly prolonged progression-free survival and overall survival in NSCLC patients—including those with EGFR or ALK genetic alterations. Moreover, the intervention's safety profile was consistent with the known risks of the medications taken alone.